Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 5,456 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Solid Malignancy Clear all
Terminated Phase 1Phase 2 Interventional Results available

Stereotactic Radiation Therapy in Treating Patients With Liver Metastases

NCT00938457
View directory record Official record
Conditions
Unspecified Adult Solid Tumor
Interventions
stereotactic radiation therapy, implanted fiducial-based imaging, cone-beam computed tomography
Radiation · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Oct 25, 2026, 5:01 AM EDT
Completed Phase 1Phase 2 Interventional

A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors

NCT02428712
View directory record Official record
Conditions
Advanced Unresectable Solid Tumors, BRAF-mutated Tumors
Interventions
FORE8394
Drug
Lead sponsor
Fore Biotherapeutics
Industry
Eligibility
10 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
13
States / cities
Scottsdale, Arizona • Orange, California • Stanford, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 25, 2026, 5:01 AM EDT
Completed Phase 1 Interventional

A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm

NCT01905228
View directory record Official record
Conditions
Solid Tumors, Glioblastoma
Interventions
CBL0137
Drug
Lead sponsor
Incuron
Industry
Eligibility
15 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
4
States / cities
Buffalo, New York • Cleveland, Ohio • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 25, 2026, 5:01 AM EDT
Not listed Phase 1 Interventional

A Study of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors

NCT03646071
View directory record Official record
Conditions
Locally Advanced Solid Tumors, Metastatic Solid Tumors
Interventions
RX108
Drug
Lead sponsor
NeuPharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Oct 25, 2026, 5:01 AM EDT
Active, not recruiting Phase 2 Interventional

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

NCT04976634
View directory record Official record
Conditions
Neoplasm Malignant
Interventions
Pembrolizumab, Belzutifan, Lenvatinib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
16
States / cities
Tucson, Arizona • Duarte, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 25, 2026, 5:01 AM EDT
Completed Phase 1 Interventional

A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors

NCT01183364
View directory record Official record
Conditions
Solid Tumor Malignancies
Interventions
STA-9090 (ganetespib) with Docetaxel
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 19, 2014 · Synced Oct 25, 2026, 5:01 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL

NCT01897571
View directory record Official record
Conditions
B-cell Lymphomas (Phase 1), Advanced Solid Tumors (Phase 1), Diffuse Large B-cell Lymphoma (Phase 2), Follicular Lymphoma (Phase 2), Transformed Follicular Lymphoma, Primary Mediastinal Large B-Cell Lymphoma
Interventions
Tazemetostat, Prednisolone
Drug
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
16 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
12
States / cities
Birmingham, Alabama • Duarte, California • Santa Barbara, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 25, 2026, 5:01 AM EDT
Active, not recruiting No phase listed Observational

Characterizing Sleep Among Long-term Survivors of Childhood Cancer

NCT05480904
View directory record Official record
Conditions
ALL, Adult, CNS Tumor, Solid Tumor
Interventions
Neurocognitive (Thinking) Testing, CNS Vital Signs (Thinking) Testing, Health Questionnaires, Sleep Surveys & Sleep Diary, Echocardiography/EKG, Pulmonary Function, Remote Polysomnography, Physical Function
Other · Diagnostic Test · Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 25, 2026, 5:01 AM EDT
Completed Phase 1 Interventional

Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

NCT04925284
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Cervical Cancer, SCCHN, Pancreatic Cancer, Esophageal SCC, Metastatic Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Tissue Factor-Expressing Solid Tumors
Interventions
XB002, Nivolumab, Bevacizumab
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
34
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 25, 2026, 5:01 AM EDT
Withdrawn Not applicable Interventional

A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors

NCT00923728
View directory record Official record
Conditions
Refractory Solid Tumors
Interventions
AVN944
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 10, 2014 · Synced Oct 25, 2026, 5:01 AM EDT
Completed Not applicable Interventional Results available

Text-based Intervention to Minimize the Time Burden of Routine Cancer Care

NCT05134636
View directory record Official record
Conditions
Cancer, Solid Tumor, Patient Empowerment, Telemedicine
Interventions
Text triage
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 25, 2026, 5:01 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors

NCT04052204
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck (SCCHN), Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions
avelumab, Bempegaldesleukin, talazoparib, enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 25, 2026, 5:01 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Promoting Physical Activity In After-School Programs for Urban Adolescents

NCT00301158
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
exercise intervention, counseling intervention, educational intervention, complementary or alternative medicine procedure
Behavioral · Other · Procedure
Lead sponsor
Montclair State University
Other
Eligibility
11 Years to 14 Years
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
1
States / cities
Montclair, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Oct 25, 2026, 5:01 AM EDT
Suspended Phase 1 Interventional

Phase I Study in Advanced Malignancies With 5-ALA

NCT04381806
View directory record Official record
Conditions
Solid Tumor
Interventions
5-ALA
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 25, 2026, 5:01 AM EDT
Recruiting Not applicable Interventional

TCF-001 TRACK (Target Rare Cancer Knowledge) Study

NCT04504604
View directory record Official record
Conditions
Rare Cancers, Cholangiocarcinoma, Cancer of Unknown Primary Site
Interventions
FoundationOne CDx and FoundationOne Liquid CDx
Diagnostic Test
Lead sponsor
TargetCancer Foundation
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 25, 2026, 5:01 AM EDT
Completed Phase 1 Interventional

Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

NCT01749384
View directory record Official record
Conditions
Solid Neoplasm
Interventions
Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study, Tivantinib
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Hershey, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Oct 25, 2026, 5:01 AM EDT
Not listed Phase 1 Interventional

YL-13027 in Patients With Advanced Solid Tumors

NCT05228600
View directory record Official record
Conditions
Solid Tumor
Interventions
YL-13027
Drug
Lead sponsor
Shanghai YingLi Pharmaceutical Co. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2022 · Synced Oct 25, 2026, 5:01 AM EDT
Completed Phase 1 Interventional

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

NCT03829436
View directory record Official record
Conditions
Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer, Renal Cell Carcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma of Head and Neck, Triple-Negative Breast Cancer, Urothelial Carcinoma, Cholangiocarcinoma, GastroEsophageal Cancer, Pancreatic Cancer, Sarcoma
Interventions
Part 1 TPST-1120, Part 2 TPST-1120 + nivolumab, Part 3 TPST-1120, Part 4 TPST-1120 + nivolumab
Drug
Lead sponsor
Tempest Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
11
States / cities
San Francisco, California • Miami, Florida • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 25, 2026, 5:01 AM EDT
Terminated Phase 1 Interventional

BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors

NCT05935098
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, Solid Tumor
Interventions
BGB-A3055, Tislelizumab, Chemotherapy
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Orlando, Florida • Iowa City, Iowa • Hackensack, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 25, 2026, 5:01 AM EDT
Completed Phase 1 Interventional

Study of TP-3654 in Patients With Advanced Solid Tumors

NCT03715504
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
TP-3654
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Houston, Texas • Salt Lake City, Utah • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 25, 2026, 5:01 AM EDT
Completed Phase 1 Interventional

Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced Solid Tumors

NCT01030055
View directory record Official record
Conditions
Neoplasms, Cancer, Tumors
Interventions
TKI258 (dovitinib)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Duarte, California • Los Angeles, California • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 25, 2026, 5:01 AM EDT
Completed Phase 1 Interventional

A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction

NCT01273493
View directory record Official record
Conditions
Neoplasm Metastases, Hepatic Insufficiency
Interventions
Trabectedin, Dexamethasone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
6
States / cities
Scottsdale, Arizona • Detroit, Michigan • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2016 · Synced Oct 25, 2026, 5:01 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

NCT04557449
View directory record Official record
Conditions
Liposarcoma, Prostate Cancer, Advanced Breast Cancer, NSCLC (Non-small Cell Lung Cancer), Colorectal Cancer
Interventions
PF-07220060, Letrozole, Fulvestrant, Midazolam, Enzalutamide, Giredestrant, Tamoxifen
Drug · Combination Product · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
14
States / cities
Los Angeles, California • New Haven, Connecticut • Trumbull, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 25, 2026, 5:01 AM EDT
Completed No phase listed Observational

Evaluating the Use of Wearable Biosensors and PROs to Assess Performance Status in Patients With Cancer

NCT02659358
View directory record Official record
Conditions
Neoplasms
Interventions
Fitbit Charge HR®
Device
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 25, 2026, 5:01 AM EDT